

Brad H Rovin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/305667/publications.pdf>

Version: 2024-02-01

145
papers

9,053
citations

57752

44
h-index

46795

89
g-index

146
all docs

146
docs citations

146
times ranked

6190
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1215-1226.	6.7	1,083
2	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	5.2	782
3	Update on Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 825-835.	4.5	560
4	Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. <i>New England Journal of Medicine</i> , 2020, 383, 1117-1128.	27.0	506
5	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	5.2	325
6	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 36-46.	27.0	324
7	Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2070-2080.	13.7	268
8	Urine Chemokines as Biomarkers of Human Systemic Lupus Erythematosus Activity. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 467-473.	6.1	236
9	Update on Lupus Nephritis: Core Curriculum 2020. <i>American Journal of Kidney Diseases</i> , 2020, 76, 265-281.	1.9	228
10	Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 1305-1313.	5.6	224
11	A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. <i>Kidney International</i> , 2019, 95, 219-231.	5.2	208
12	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	5.2	198
13	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1306-1313.	6.1	174
14	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , 2015, 2, e000123-e000123.	2.7	155
15	B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 100-107.	0.9	154
16	Histologic versus clinical remission in proliferative lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1338-1344.	0.7	152
17	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	5.2	135
18	A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. <i>Kidney International</i> , 2018, 94, 788-794.	5.2	110

#	ARTICLE	IF	CITATIONS
19	MG53-mediated cell membrane repair protects against acute kidney injury. <i>Science Translational Medicine</i> , 2015, 7, 279ra36.	12.4	103
20	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1595-1602.	4.5	103
21	Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212599.	0.9	98
22	Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2228-2234.	0.7	93
23	Renal Flare as a Predictor of Incident and Progressive CKD in Patients with Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 279-284.	4.5	92
24	Biomarkers for Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1858-1865.	4.5	90
25	Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. <i>Kidney International</i> , 2021, 99, 1487.	5.2	90
26	Lupus Nephritis: The Evolving Role of Novel Therapeutics. <i>American Journal of Kidney Diseases</i> , 2014, 63, 677-690.	1.9	87
27	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 496-506.	0.9	87
28	A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. <i>Kidney International</i> , 2016, 90, 493-501.	5.2	80
29	A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. <i>Kidney International</i> , 2022, 101, 403-413.	5.2	80
30	Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. <i>Clinical Chemistry</i> , 2017, 63, 1515-1526.	3.2	76
31	Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. <i>Kidney International</i> , 2020, 97, 156-162.	5.2	72
32	Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. <i>Kidney International</i> , 2020, 98, 233-234.	5.2	67
33	A reference tissue atlas for the human kidney. <i>Science Advances</i> , 2022, 8, .	10.3	67
34	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	4.5	66
35	Staphylococcus-Related Glomerulonephritis and Poststreptococcal Glomerulonephritis: Why Defining "Post" Is Important in Understanding and Treating Infection-Related Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2015, 65, 826-832.	1.9	65
36	Staphylococcus Infection-Associated GN "Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 39-49.	4.5	65

#	ARTICLE	IF	CITATIONS
37	COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?. <i>Kidney International</i> , 2021, 100, 959-965.	5.2	65
38	Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1335-1347.	6.1	63
39	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	2.7	62
40	A multimodal and integrated approach to interrogate human kidney biopsies with rigor and reproducibility: guidelines from the Kidney Precision Medicine Project. <i>Physiological Genomics</i> , 2021, 53, 1-11.	2.3	59
41	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. <i>Arthritis Care and Research</i> , 2016, 68, 1003-1011.	3.4	54
42	Biomarker discovery in human SLE nephritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65, 187-93.	0.7	54
43	Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 147-153.	4.5	50
44	Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 47-53.	4.5	49
45	Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i71-i79.	0.7	46
46	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. <i>Arthritis and Rheumatology</i> , 2019, 71, 411-419.	5.6	45
47	Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. <i>Kidney International Reports</i> , 2019, 4, 1152-1160.	0.8	44
48	Hurdles to the introduction of new therapies for immune-mediated kidney diseases. <i>Nature Reviews Nephrology</i> , 2016, 12, 205-216.	9.6	43
49	Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 387-392.	2.2	43
50	New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. <i>Arthritis and Rheumatology</i> , 2017, 69, 487-493.	5.6	42
51	Early experience with COVID-19 in kidney transplantation. <i>Kidney International</i> , 2020, 97, 1074-1075.	5.2	41
52	The lupus nephritis management renaissance. <i>Kidney International</i> , 2022, 101, 242-255.	5.2	40
53	Cyclopentenone Prostaglandins Inhibit Cytokine-Induced NF- κ B Activation and Chemokine Production by Human Mesangial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1659-1667.	6.1	39
54	Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. <i>Lupus Science and Medicine</i> , 2015, 2, e000112-e000112.	2.7	38

#	ARTICLE	IF	CITATIONS
55	Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis. <i>Proteomics - Clinical Applications</i> , 2015, 9, 1012-1020.	1.6	37
56	Why Target the Gut to Treat IgA Nephropathy?. <i>Kidney International Reports</i> , 2020, 5, 1620-1624.	0.8	37
57	B-cell therapy in lupus nephritis: an overview. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 22-29.	0.7	35
58	The Kidney Biopsy in Lupus Nephritis. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 537-552.	1.9	33
59	Molecular characterization of the human kidney interstitium in health and disease. <i>Science Advances</i> , 2021, 7, .	10.3	33
60	Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. <i>Translational Research</i> , 2017, 182, 1-13.	5.0	29
61	Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2123-2129.	0.7	28
62	Validation of the Lupus Nephritis Clinical Indices in Childhood Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 195-202.	3.4	27
63	Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 244-254.	5.6	27
64	Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial). <i>Kidney International Reports</i> , 2019, 4, 1633-1637.	0.8	26
65	Low-Grade Proteinuria Does Not Exclude Significant Kidney Injury in Lupus Nephritis. <i>Kidney International Reports</i> , 2020, 5, 1066-1068.	0.8	26
66	The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 360-368.	1.4	25
67	Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1197-1206.	0.7	24
68	Rethinking Lupus Nephritis Classification on a Molecular Level. <i>Journal of Clinical Medicine</i> , 2019, 8, 1524.	2.4	21
69	Standardized Outcomes in Nephrology Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	5.2	20
70	Expanding the Role of Complement Therapies: The Case for Lupus Nephritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 626.	2.4	19
71	Can We Personalize Treatment for Kidney Diseases?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1670-1676.	4.5	18
72	Oral Warfarin and the Thrombin Inhibitor Dabigatran Increase Blood Pressure in Rats: Hidden Danger of Anticoagulants?. <i>American Journal of Hypertension</i> , 2015, 28, 182-189.	2.0	18

#	ARTICLE	IF	CITATIONS
73	Anticoagulant-Related Nephropathy in Kidney Biopsy: A Single-Center Report of 41 Cases. <i>Kidney Medicine</i> , 2019, 1, 51-56.	2.0	18
74	Prediction models of treatment response in lupus nephritis. <i>Kidney International</i> , 2022, 101, 379-389.	5.2	18
75	Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, F505-F516.	2.7	16
76	Of Mice and Men: The Relevance of the Mouse to the Study of Human SLE. <i>Immunologic Research</i> , 2001, 24, 211-224.	2.9	15
77	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. <i>Lupus Science and Medicine</i> , 2019, 6, e000342.	2.7	15
78	Preserved Renal Allograft Function and Successful Treatment of Metastatic Merkel Cell Cancer Post Nivolumab Therapy. <i>Transplantation</i> , 2019, 103, e52-e53.	1.0	15
79	Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. <i>Arthritis Care and Research</i> , 2021, 73, 146-157.	3.4	15
80	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2022, 79, 570-581.	1.9	15
81	The cell membrane repair protein MG53 modulates transcription factor NF- κ B signaling to control kidney fibrosis. <i>Kidney International</i> , 2022, 101, 119-130.	5.2	14
82	Expert Perspective: An Approach to Refractory Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 915-926.	5.6	14
83	Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. <i>Kidney International Reports</i> , 2018, 3, 1057-1063.	0.8	13
84	Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1168-1175.	0.7	13
85	Induction Therapy for Lupus Nephritis: the Highlights. <i>Current Rheumatology Reports</i> , 2018, 20, 60.	4.7	13
86	Induction and maintenance therapy of lupus nephritis: an obituary. <i>Kidney International</i> , 2021, 99, 288-291.	5.2	13
87	Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. <i>Thrombosis Research</i> , 2021, 201, 50-59.	1.7	13
88	MG53 protects against contrast-induced acute kidney injury by reducing cell membrane damage and apoptosis. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1457-1464.	6.1	13
89	A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis. <i>Frontiers in Immunology</i> , 2021, 12, 621039.	4.8	11
90	Oral Cyclophosphamide Is on the Verge of Extinction as Therapy for Severe Autoimmune Diseases (Especially Lupus): Should Nephrologists Care?. <i>Nephron Clinical Practice</i> , 2010, 117, c8-c14.	2.3	10

#	ARTICLE	IF	CITATIONS
91	Application of Laser Microdissection to Uncover Regional Transcriptomics in Human Kidney Tissue. Journal of Visualized Experiments, 2020, , .	0.3	9
92	Beyond anemia: hepcidin, monocytes and inflammation. Biological Chemistry, 2013, 394, 1-10.	2.5	8
93	Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. Lupus Science and Medicine, 2019, 6, e000308.	2.7	8
94	Do kidneys grow old gracefully?. Kidney International, 2020, 97, 40-41.	5.2	8
95	Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy. Kidney International Reports, 2021, 6, 2653-2660.	0.8	8
96	Targeting B-cells in lupus nephritis: should cautious optimism remain?. Nephrology Dialysis Transplantation, 2013, 28, 7-9.	0.7	7
97	The Urine Preservative Acetic Acid Degrades Urine Protein: Implications for Urine Biorepositories and the AASK Cohort Study. Journal of the American Society of Nephrology: JASN, 2017, 28, 1394-1398.	6.1	7
98	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
99	Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. CKJ: Clinical Kidney Journal, 2015, 8, 492-502.	2.9	6
100	Advances and Challenges on New Therapies and Clinical Targets of Acute Kidney Injury. Toxicologic Pathology, 2018, 46, 925-929.	1.8	5
101	Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1228-1239.	0.8	5
102	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney International, 2021, 99, 519-523.	5.2	4
103	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
104	Bath Salts: A Newly Recognized Cause of Acute Kidney Injury. Case Reports in Nephrology, 2012, 2012, 1-5.	0.4	3
105	A78: Urine Biomarkers Role in Predicting the Future Development of Renal Functional Loss With Lupus Nephritis in Children and Adults. Arthritis and Rheumatology, 2014, 66, S111-S111.	5.6	3
106	Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Nephrology (Saint-Petersburg), 2021, 25, 96-119.	0.4	3
107	Patients with Proliferative Lupus Nephritis Have Autoantibodies That React to Moesin and Demonstrate Increased Glomerular Moesin Expression. Journal of Clinical Medicine, 2021, 10, 793.	2.4	3
108	MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNPO23 IN PRIMARY IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	3

#	ARTICLE	IF	CITATIONS
109	A challenge to the kidney community by a man-made crisis. <i>Kidney International</i> , 2022, 101, 854-855.	5.2	3
110	Controversies in Systemic Lupus Erythematosus 2021. <i>Journal of Clinical Rheumatology</i> , 2022, 28, 229-233.	0.9	3
111	Kidney International celebrates the 60th anniversary of the International Society of Nephrology. <i>Kidney International</i> , 2019, 96, 1248-1249.	5.2	2
112	Response to: "Lack of standardization of ANA and implications for drug development and precision medicine" by Mahler. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e34-e34.	0.9	2
113	Response to "Antinuclear antibodies by indirect immunofluorescence and solid phase assays" by Bossuyt et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e66-e66.	0.9	2
114	Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. <i>Kidney International Reports</i> , 2020, 5, 1302-1305.	0.8	2
115	Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients. <i>Scientific Reports</i> , 2020, 10, 20202.	3.3	2
116	The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. <i>Kidney International Reports</i> , 2021, 6, 2105-2113.	0.8	2
117	Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1484-F1492.	2.7	1
118	Response to: "Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities" by Bossuyt et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e77-e77.	0.9	1
119	Response to: "Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis" by van Hoovels et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e49-e49.	0.9	1
120	A tolvaptan skeptic repents. <i>Kidney International</i> , 2020, 98, 293.	5.2	1
121	LB001 EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
122	Kidney International and the COVID-19 infection. <i>Kidney International</i> , 2020, 97, 823.	5.2	1
123	Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. <i>Kidney International</i> , 2021, 99, 2-4.	5.2	1
124	Looking back and moving forward. <i>Kidney International</i> , 2021, 99, 787-790.	5.2	1
125	The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy. <i>Kidney International</i> , 2021, 99, 811-813.	5.2	1
126	FC 034 SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS: A 6-MONTH OPEN-LABEL EXTENSION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	1

#	ARTICLE	IF	CITATIONS
127	The Use of Serological Tests in the Care of Patients with Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 305-307.	4.5	1
128	Membranoproliferative Glomerulonephritis With Changing Immunofluorescence Pattern. <i>Kidney International Reports</i> , 2022, 7, 1123-1127.	0.8	1
129	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. <i>Kidney International Reports</i> , 2022, 7, 2076-2080.	0.8	1
130	Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Fcγ2b Therapy: Results From the Phase 1b/2a M-PLACE Study. <i>Kidney International Reports</i> , 2022, .	0.8	1
131	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 1507-1508.	5.6	0
132	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 2247-2248.	5.6	0
133	AI-06...Lupus nephritis is linked to dysbiosis, increased gut leakiness and immunity to an intestinal commensal lachnospiraceae species. , 2018, , .		0
134	Response to: "Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study" by Pregalato et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e51-e51.	0.9	0
135	The authors reply. <i>Kidney International</i> , 2019, 95, 992-993.	5.2	0
136	Response to: "Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?" by Meroni et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e47-e47.	0.9	0
137	Response to: "ANA testing in real life" by Infantino et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e4-e4.	0.9	0
138	Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e7-e7.	0.9	0
139	Response to: "Can solid-phase assays replace immunofluorescence for ANA screening?" by Bizzaro. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e33-e33.	0.9	0
140	In this issue "2020 draws to a close. <i>Kidney International</i> , 2020, 98, 1361.	5.2	0
141	Variability in the B cell receptor repertoire across immune-mediated diseases. <i>Kidney International</i> , 2020, 98, 536-538.	5.2	0
142	Letter to the Editor. <i>Kidney International Reports</i> , 2020, 5, 2121.	0.8	0
143	Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab. <i>Kidney International Reports</i> , 2020, 5, 951-954.	0.8	0
144	The authors reply. <i>Kidney International</i> , 2020, 97, 807.	5.2	0

#	ARTICLE	IF	CITATIONS
145	The authors reply. <i>Kidney International</i> , 2021, 99, 1242.	5.2	0